Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
Should you invest $1,000 in right now?
Before you consider , you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Here’s why the Next Science (ASX:NXS) share price is rocketing 11% today
What happened to the Next Science (ASX:NXS) share price last earnings season?
Next Science (ASX:NXS) share price jumps on record revenue growth
Next Science (ASX:NXS) share price swings on lowered earnings update
Here’s why the Next Science (ASX:NXS) share price finished higher today
Next Science (ASX:NXS) share price falls despite ‘exciting future ahead’
Why Doctor Care Anywhere, Next Science, NIB, & Talga are charging higher
Why the Next Science (ASX:NXS) share price opened 40% higher
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.
|16 May 2022||$0.87||$-0.03||-3.37%||26,092||$0.89||$0.89||$0.87|
|13 May 2022||$0.89||$0.02||2.30%||19,910||$0.87||$0.89||$0.86|
|12 May 2022||$0.87||$0.00||0.00%||42,371||$0.88||$0.90||$0.87|
|11 May 2022||$0.87||$0.02||2.35%||43,407||$0.87||$0.90||$0.87|
|10 May 2022||$0.85||$-0.01||-1.17%||52,913||$0.85||$0.90||$0.85|
|09 May 2022||$0.86||$-0.04||-4.49%||26,899||$0.89||$0.89||$0.86|
|06 May 2022||$0.89||$-0.01||-1.11%||27,016||$0.90||$0.90||$0.89|
|05 May 2022||$0.90||$0.00||0.00%||40,214||$0.89||$0.91||$0.88|
|04 May 2022||$0.90||$0.02||2.26%||77,956||$0.90||$0.91||$0.90|
|03 May 2022||$0.89||$0.00||0.00%||9,152||$0.89||$0.89||$0.89|
|02 May 2022||$0.89||$0.00||0.00%||66,052||$0.89||$0.89||$0.89|
|29 Apr 2022||$0.89||$0.02||2.30%||83,380||$0.89||$0.93||$0.89|
|28 Apr 2022||$0.87||$0.03||3.55%||136,550||$0.86||$0.90||$0.86|
|27 Apr 2022||$0.85||$-0.06||-6.67%||26,713||$0.87||$0.90||$0.85|
|26 Apr 2022||$0.90||$0.06||7.14%||262,204||$0.82||$0.90||$0.82|
|22 Apr 2022||$0.84||$0.02||2.42%||102,711||$0.83||$0.84||$0.80|
|21 Apr 2022||$0.83||$-0.02||-2.38%||47,855||$0.83||$0.86||$0.83|
|20 Apr 2022||$0.84||$0.03||3.70%||59,402||$0.81||$0.84||$0.80|
|30 Mar 2022||Judith Mitchell||Sell||140||$123,310||
|29 Mar 2022||Mark Compton||Buy||34||$29,999||
Participation in share purchase plan.
|29 Mar 2022||Bruce Hancox||Buy||34||$29,999||
Participation in share purchase plan.
|29 Mar 2022||Daniel (Dan) Spira||Buy||28||$27,872||
Participation in share purchase plan.
|Mr Mark Raymond Compton||Non-Executive DirectorNon-Executive Chairman||Oct 2018||
Mr Compton is Lord Prior of the International Order of St John and Chairman of the Board of Trustees of St John International. He is also Chairman of St Luke's Care Limited and Chairman of Integrated Clinical Oncology Network Pty Ltd trading as Icon Cancer Centre. Mark has held range of CEO and managing director roles, including at St Luke's Care Limited, Immune System Therapeutics Limited, Royal Flying Doctor Service of Australia, SciGen Limited and Alpha Healthcare Limited. He is an Adjunct Professor at Macquarie University in healthcare leadership and management (since 2012). He is a member of People, Culture Committee.
|Mr Bruce Alan Hancox||Non-Executive Director||Oct 2017||
Mr Hancox has over 35 years of corporate experience across commerce, including 16 years with Brierley Investments Limited in New Zealand. He held a number of senior roles at Brierley Investments as general manager and Chairman and served on the board of a number of their subsidiaries in New Zealand, Australia and the US. Bruce has been a financial advisor to interests of Mr Langley Walker since 2008. He serves as a director of investments and wealth management at Walker Corporation Pty Ltd and works with the Walker group of companies to pursue investment opportunities outside the property market. He is a Director of Walker Group Holdings Pty Limited. He is Chair of the Risk Committee.
|Mr Daniel (Dan) Spira||Non-Executive Director||Oct 2017||
Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM North America and was also Managing Director, Pacific region. Prior to that, Daniel spent over 15 years at Johnson & Johnson Inc in range of roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions. He is a Chair of People, Culture Committee.
|Mrs Aileen Stockburger||Non-Executive Director||Oct 2018||
Mrs Stockburger was the Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. She led Johnson & Johnson's efforts to acquire Synthes. She also led the efforts to divest the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also part of range of other M&A transactions including Pfizer Consumer Healthcare, Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. He is a Non-Executive Director of Microbot Medical Inc. She is a member of Risk Committee.
|Ms Judith Mitchell||Managing Director||Oct 2017||
Ms Mitchell served as President of DePuy Synthes Asia Pacific, the Orthopaedics Division of Johnson & Johnson, before which Judith was President of Asia Pacific for Synthes GmbH. Judith commenced her medical technology career at GE Medical Systems, where over 14 years, she held positions in sales, marketing and management. She also held a range of positions at Cochlear Limited in Product Development, Global Marketing and Education.
|Ms Gillian Maria Nairn||Company Secretary||Jun 2018||
|Dustin Haines||Chief Commercial Officer||
|Jacqueline Butler||Chief Financial Officer||
|Jon Swanson||Chief Operating Officer||
|Matthew Myntti||Chief Technology Officer||
|Gillian Maria Nairn||Company Secretary||
|Auckland Trust Company Ltd ATF Secord Pacific Master Superannuation Fund||56,019,938||28.85%|
|Walker Group Holdings Pty Limited||21,719,667||11.18%|
|HSBC Custody Nominees (Australia) Limited A/C 2||6,299,588||3.24%|
|Merrill Lynch (Australia) Nominees Pty Limited||5,130,056||2.64%|
|HSBC Custody Nominees (Australia) Limited||3,534,393||1.82%|
|UBS Nominees Pty Ltd||3,464,130||1.78%|
|Mr Charles Robert Dirck Wittenoom||2,825,000||1.45%|
|National Nominees Limited||2,443,875||1.26%|
|Citicorp Nominees Ply Limited||1,637,135||0.84%|
|Scone Investments Pty Ltd||1,159,452||0.60%|
|G & N Lord Superannuation Pty Ltd <GNR Superannuation Fund A/C>||965,000||0.50%|
|Mr Byron James Darroch||962,500||0.50%|
|Ka-tet Pty Ltd <The Rosenrot Trust>||890,500||0.46%|
|Insync Investments Pty Ltd <Weekley Super Fund No 1 A/C>||625,000||0.32%|
|Authentics Australia Pty Ltd <Authentics Australia A/C>||512,438||0.26%|
|Tsunami Ventures Pty Ltd <Drizzle Family A/C>||500,938||0.26%|
|Honne Investments Pty Limited||500,000||0.26%|